Literature DB >> 11394500

Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens.

L A Lambert1, G R Gibson, M Maloney, R J Barth.   

Abstract

Multiple clinically applicable methods have been used to induce dendritic cells (DCs) to express whole cell tumor antigens, including pulsing DCs with tumor lysate, and mixing DCs with apoptotic or live tumor cells. Herein we demonstrate, using two different tumor systems, that these methods are equipotent inducers of systemic antitumor immunity. Furthermore, tumor lysate pulsed DC vaccines generate more potent antitumor immunity than immunization with irradiated tumor cells plus the classic adjuvant, Corynebacterium parvum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394500

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  3 in total

Review 1.  DNA vaccines for HIV: challenges and opportunities.

Authors:  David A Hokey; David B Weiner
Journal:  Springer Semin Immunopathol       Date:  2006-10-10

2.  A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.

Authors:  Richard J Barth; Dawn A Fisher; Paul K Wallace; Jacqueline Y Channon; Randolph J Noelle; Jiang Gui; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2010-09-30       Impact factor: 12.531

3.  Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.

Authors:  Andreas Lundqvist; Andreas Palmborg; Gawa Bidla; Mike Whelan; Hardev Pandha; Pavel Pisa
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.